Navigation Links
NeurogesX Reports First Quarter 2011 Results

e Act. Examples of such statements include but are not limited to: statements regarding expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza, expectations regarding the Company's Phase 2 clinical trial of NGX-1998 and expected operating expenses, including moderated expense growth, for 2011.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to the successful marketing or manufacture and supply of Qutenza; physician or patient reluctance to use Qutenza, despite efforts and strategies to commercialize Qutenza; difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submission of the sNDA for Qutenza; and difficulties or delays in the clinical development of NGX-1998.  For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. NEUROGESX, INC.Condensed Consolidated Statements of Operations(in thousands, except share and per share information)Three Months EndedMarch 31,20112010 Net product revenue

8212; Collaboration revenue

2,5951,786Total revenue

3,1701,786Operating expenses:Cost of goods sold

108—Research and development

3,9572,123Selling, general and administrative

10,2828,806Total operating expenses

14,34710,929Loss from operations

(11,177)(9,143)Interest income

278Interest expense

(2,200)(4)Other income (expense), net

(13)(24)Net loss

(9,163)Basic and diluted net loss per share$
(0.52)Shares used to compute basic and diluted net loss per share


SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
3. NeurogesX to Provide Qutenza® Launch Update
4. NeurogesX to Present at Two February Investor Conferences
5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Innovations, LLC, a leading developer and marketer of high ... of their new European office in Enschede, the Netherlands ... management team and new European staff, local Enschede dignitaries ... of Economic Affairs in The Netherlands and Mr. Jan ...
... 31, 2011 Omni Bio Pharmaceutical, Inc. (OTC BB: OMBP), ... To the Shareholders of Omni Bio Pharmaceutical, Inc.: ... first month as the Chief Executive Officer of Omni Bio ... a close, this is an appropriate juncture to update our ...
Cached Medicine Technology:Freedom Innovations Opens New European Headquarters 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 3Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 4Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 5Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 6
(Date:12/24/2014)... Today,, the famous women’s dress supplier, has presented its ... site-wide wedding gown promotion. , For those who ... unexpected way, the collection should be a great choice. The ... and they are available with custom service. , Now, all ... up to 75% off; most of them come in hot ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A lab ... Prevention may have been exposed to the Ebola virus ... And up to a dozen other lab workers ... late Wednesday afternoon. The possible exposure occurred Monday ... a sample of the potentially lethal virus to another ...
Breaking Medicine News(10 mins):Health News:Buy Cheap Long Sleeve Wedding Gowns At 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... for Helicobacter pylori as the decay-accelerating factor (DAF), a ... , Blocking this interaction could lead to new drugs ... gastric cancer. The research appears as the ‘Paper of ... Journal of Biological Chemistry, an American Society for Biochemistry ...
... In a new clinical development partnership being launched ... arm, Cancer Research Technology (CRT) plans to take ... for not showing enough commercial promise following their ... new treatments from anti-cancer drugs that have been ...
... by the defence attorneys of the AIIMS hospital, has sought ... where a boy, suffering from cancer, got inflicted with AIDS ... ,The victim, who was nine years old at the ... for treatment of cancer, supposedly has contracted HIV due to ...
... drug Zoloft (sertraline) may avoid in preventing recurring of ... interval between the depressive episodes. ,One in every ... the study, reports ,Researchers studied 152 ... recovered from depression during treatment with Zoloft -- 79 ...
... recent conducted at University of Michigan Health Systems in ... greater expectations of doom from their screening //mammography for ... not these expectations were unusually high or unrealistic. ... an outpatient clinic for screening mammography. The participants were ...
... Computer keyboards used in hospitals are a reservoir for ... to be disinfected every day, a new study warns.// ... various locations inside University of North Carolina hospitals and ... two types of bacteria, reports the science portal HealthCentral. ...
Cached Medicine News:Health News:Receptor for H.pylori Identified in Stomach 2Health News:Cancer Research UK Offers New Hope To Cancer Patients 2Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:Most Women Have Unrealistic Expectations From Screening Mammography 2Health News:Computer Keyboards In Hospitals Could Spread Infection To Patients 2
... a convenient, reusable, patient-friendly and effective ... orthopedic conditions/instabilities. These products are designed ... lateral to medial influence of cutaneous ... and soft tissue structures. Maximum benefit ...
... state-of-the-art laser scanning technology for an anatomically-contoured, ... lean, athletic legs. Offering the same ... Flex Sport's "second skin" fit conforms to ... no other off-the-shelf knee brace., ,Indications: ...
... Drytex Adjustable Patella Donut is a ... nylon core and polyester Lycra Fabric ... trimable full-circumference donut provides for patellar ... neoprene based allergies or irritations. Click ...
... of the Custom Montana2 alleviates the ... three-point load across the knee joint, ... area. The Diagonal Loading Strap gives ... the load to accommodate their daily ...
Medicine Products: